Plant Name: Stellaria media
Taxonomic Information:
Plant ID: NPO12223
Plant Latin Name: Stellaria media
Taxonomy Genus: Stellaria
Taxonomy Family: Caryophyllaceae
Plant External Links:
NCBI TaxonomyDB:
13274
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Pakistan; Italy; India; Finland; Lebanon; Chile; Argentina; BulgariaTraditional Medicine System:
Indian Folk; HomeopathyMedicinal Functions:
Antirheumatic; Astringent; Carminative; Demulcent; Depurative; Diuretic; Emmenagogue; Expectorant; Galactogogue; Kidney; Laxative; Ophthalmic; Poultice; Refrigerant; TB; Vulnerary
Geographical Distribution:
Pakistan; Italy; Lebanon; Finland; India; Chile; Argentina; Bulgaria
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR7; HTR5A; HTR2B; HTR1A; DRD1; HTR6; HCAR2; | |
| TDP1; CDA; | |
| CA1; CA7; CA14; CA12; CA9; CA2; | |
| MMP2; MMP9; | |
| CREBBP; | |
| F3; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Bromodomain | CREBBP | CREB-binding protein | Q92793 | CHEMBL5747 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.599E-12 | 2.830E-08 | CA1, CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 2.182E-11 | 6.786E-08 | HTR1A, HTR2B, HTR5A, HTR6, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 2.182E-11 | 6.786E-08 | HTR1A, HTR2B, HTR5A, HTR6, HTR7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.921E-10 | 4.348E-07 | CA1, CA12, CA2, CA7, CA9 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 2.196E-10 | 4.348E-07 | HTR1A, HTR2B, HTR5A, HTR7 |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 3.225E-09 | 4.682E-06 | HTR1A, HTR5A, HTR7 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.506E-08 | 3.032E-05 | CA1, CA12, CA2, CA7, CA9, CDA, CREBBP, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.748E-06 | 2.494E-03 | CA2, CA7 |
| BP | Unclassified; | GO:0042310; vasoconstriction | 2.901E-06 | 2.527E-03 | HTR1A, HTR2B, HTR7 |
| CC | GO:0016020; membrane | GO:0005886; plasma membrane | 3.551E-06 | 2.896E-03 | CA12, CA14, CA2, CA9, DRD1, F3, HCAR2, HTR1A, HTR2B, HTR5A, HTR6, HTR7, MMP2, TDP1 |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 5.820E-06 | 4.224E-03 | DRD1, HTR1A, HTR2B, HTR7 |
| BP | GO:0032501; multicellular organismal process | GO:0006939; smooth muscle contraction | 1.357E-05 | 7.286E-03 | DRD1, HTR2B, HTR7 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.372E-05 | 7.286E-03 | CA1, CA2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.874E-15 | 4.081E-11 | CA1, CA12, CA14, CA2, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.757E-15 | 2.104E-13 | CA12, CA1, CA2, CA7, CA9, CA14 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 5.498E-08 | 1.539E-06 | HTR6, HTR7, HTR1A, HTR2B, HTR5A |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.559E-07 | 2.911E-06 | HTR6, HTR7, HTR1A, HTR2B, DRD1, HTR5A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 5.863E-07 | 8.209E-06 | HTR6, HTR7, HTR2B, DRD1, HTR5A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 9.628E-07 | 1.078E-05 | HCAR2, CREBBP, HTR6, HTR1A, DRD1 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 6.858E-04 | 6.401E-03 | MMP2, MMP9 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR6; HTR1A; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B; |
| NA: NA | Cervical dystonia | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR1A; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HCAR2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| NA: NA | Episode | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2B; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; HTR6; |
| NA: NA | Schizoaffective disorder | NA | HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; HCAR2; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A; |
| NA: NA | Bulimia nervosa | NA | HTR1A; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HCAR2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| NA: NA | Social phobia | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; HCAR2; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | HTR6; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR6; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | HTR1A; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; DRD1; HTR6; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; HTR1A; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; F3; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MMP9; MMP2; CA1; CA9; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP9; CDA; MMP2; CA9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HCAR2; |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | HTR1A; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B; |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2B; HTR1A; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A; |
| C00-D49: Neoplasms | Chronic myeloid leukemia | NA | CREBBP; |
| NA: NA | Anxiety disorders | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR6; HTR1A; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | CREBBP; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; HTR6; HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
